Fc N-Terminal Protein Conjugates for Stable Long-Acting Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing protein drugs face issues with low stability and short duration in the bloodstream, leading to frequent injections and potential immune reactions, and current stabilization methods using PEG polymers can reduce efficacy and cause isomerization.
Innovation Solution
A method is developed to link a physiologically active polypeptide to the N-terminus of an immunoglobulin Fc region via a non-peptidyl polymer, specifically through covalent bonds, to enhance in vivo duration and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If PEG polymers are used to stabilize proteins and increase blood concentration duration, then protein stability and solubility are improved, but the titer of the physiologically active protein is remarkably reduced and linkage isomerization occurs
Solution Approach 1:
The patent applies local quality by specifying that PEG polymers should be attached to particular sites on the protein molecule (such as N-terminal or C-terminal regions) rather than randomly throughout the structure. This site-specific conjugation ensures that the stabilizing effect of PEG is achieved while minimizing interference with the protein's active sites and functional regions, thereby maintaining drug efficacy while improving stability and blood concentration duration.
2Stability of the object's composition
If PEG polymers are bound to proteins to prevent hydrolysis and increase solubility, then protein stability is improved, but binding at multiple possible sites causes linkage isomerization and heterogeneous conjugates
Solution Approach 1:
The patent implements local quality by designing the protein structure with specific attachment sites that are localized to particular regions (e.g., engineered cysteine residues at specific positions, or terminal amino groups). This localization ensures that PEG conjugation occurs at predetermined sites only, producing homogeneous conjugates with consistent structure and properties, thereby eliminating linkage isomerization and improving manufacturing precision.
Solution Approach 2:
The patent applies preliminary action by pre-modifying the protein with specific chemical groups or engineered residues at predetermined locations before PEG conjugation. For example, the protein may be pre-engineered with cysteine mutations at specific sites or pre-activated with reactive groups that will selectively bind PEG. This preliminary preparation ensures that subsequent PEG attachment occurs only at the intended sites, guaranteeing conjugate homogeneity and eliminating the need for complex purification to remove isomers.
3Reliability
If protein drugs are administered frequently to maintain blood concentration, then pharmacological efficacy is maintained, but patient suffering increases
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of the protein drug through PEG conjugation. Specifically, the attachment of hydrophilic PEG polymers increases the drug's solubility, reduces immunogenicity, and most importantly, significantly extends the circulation half-life in blood. This parameter modification allows the drug to maintain therapeutic blood concentrations for much longer periods, enabling less frequent administration and thereby improving patient convenience while maintaining pharmacological efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The protein complex achieves improved in vivo duration and stability, allowing for long-acting formulations with minimal immune response and maintaining high efficacy.
Implementation Method 1
linking a physiologically active polypeptide to the N-terminus of an immunoglobulin Fc region via a non-peptidyl polymer, specifically through covalent bonds
Data Source
AI summary
Provided is a complex composition, of which positional isomers are minimized by using a N-terminus of an immunoglobulin Fc region as a binding site when the immunoglobulin Fc region is used as a carrier. Also provided are a protein complex which is prepared by N-terminal-specific binding of immunoglobulin Fc region, thereby prolonging blood half-life of the physiologically active polypeptide, maintaining in vivo potency at a high level, and having no risk of immune responses, a preparation method thereof, and a pharmaceutical composition including the same for improving in vivo duration and stability of the physiologically active polypeptide. The protein complex may be usefully applied to the development of long-acting formulations of various physiologically active polypeptide drugs.